Monopar Therapeutics

Forecast & Rating13 analysts currently cover Monopar Therapeutics, with about 92.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $126.31, about 10.9% upside from the current price of $113.94. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 34.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Monopar Therapeutics closely still see room for the stock to rise. Data as of Aug 17, 2026; for reference only and not investment advice.